Daraxonrasib · Rasonque

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Pancreatic Ductal Adenocarcinoma (label: metastatic disease after at least one prior systemic therapy, or not a candidate for multiagent...)

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Non-Small Cell Lung Cancer · Phase 3

Company guidance: topline data expected in 2027 (NCT06881784; Revolution Medicines, 5 Aug 2026). “Enrollment in the global Phase 3 RASolve 301 trial evaluating daraxonrasib in patients with previously treated RAS mutant NSCLC is expected to be completed this year, supporting an anticipated initial readout in 2027.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (5)
Non-Small Cell Lung Cancer
Pancreatic Ductal Adenocarcinoma
NCT07252232 · Revolution Medicines, Inc.
2025-12-15 – 2030-07-10 · Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma
What this study did
NCT07805954 · Revolution Medicines, Inc.
2026-08-28 – 2030-04 · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
What this study did
NCT07491445 · Revolution Medicines, Inc.
2026-03-09 – 2029-03 · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
What this study did
Phase 2 (3)
Other / comorbidity
NCT07908550 · National Health Research Institutes, Taiwan
2027-01 – 2030-12 · Biliary Tract Cancer (BTC)
What this study did
NCT07793253 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2026-11 – 2030-11 · Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma, Ampulla of Vater Carcinoma, Ampullary Carcinoma
What this study did
Phase 1/2 (7)
Non-Small Cell Lung Cancer
NCT07397338 · Revolution Medicines, Inc.
2026-01-30 – 2029-05 · Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC, Colorectal Cancer (CRC), CRC
What this study did
NCT06162221 · Revolution Medicines, Inc.
2024-01-18 – 2028-12 · Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC
What this study did
Pancreatic Ductal Adenocarcinoma
NCT06445062 · Revolution Medicines, Inc.
2024-05-24 – 2030-03-30 · Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
NCT06128551 · Revolution Medicines, Inc.
2023-11-14 – 2029-06 · Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
What this study did
NCT06922591 · Tango Therapeutics, Inc.
2025-05-31 – 2027-12 · PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer Metastatic, Thoracic Cancer
What this study did
NCT05379985 · Revolution Medicines, Inc.
2022-05-31 – 2027-07-26 · Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
What this study did
Other / comorbidity
NCT07819838 · Children's Oncology Group
2027-04-09 – 2032-04-09 · Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Neuroblastoma, Recurrent Childhood Rhabdomyosarcoma, Refractory Childhood Malignant Solid Neoplasm, Refractory Childhood Neuroblastoma, Refractory Childhood Rhabdomyosarcoma
What this study did
Phase 1 (5)
Pancreatic Ductal Adenocarcinoma
NCT07898813 · Dana-Farber Cancer Institute
2027-04-13 – 2029-08-13 · Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Resectable Pancreatic Ductal Adenocarcinoma
What this study did
NCT07349537 · Revolution Medicines, Inc.
2026-01-08 – 2028-10 · Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), PDAC, CRC, NSCLC, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Solid Tumors
What this study did
NCT06040541 · Revolution Medicines, Inc.
2023-09-07 – 2027-04-30 · Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
What this study did
Other / comorbidity
NCT07756281 · ParVation Therapeutics, Inc.
2026-09-01 – 2029-06-01 · Pancreatic Cancer, Pancreatic Acinar Carcinoma
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Pancreatic Ductal Adenocarcinoma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Daraxonrasib (Rasonque): this drugApprovedSmall moleculepan-RAS, RAS (pan-RAS, RAS-mutant tumors)Partial signalNo reviewed efficacy summary in this indication
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)not yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
INCB161734Phase 3Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
QuemliclustatPhase 3Small moleculeCD73 (NT5E)not yet gradedNo reviewed efficacy summary in this indication
SetidegrasibPhase 3Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
Tambotatug PelitecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
NavlimetostatPhase 2/3Small moleculePRMT5 (protein arginine methyltransferase 5), MTA-cooperative bindingnot yet gradedNo reviewed efficacy summary in this indication
Autogene CevumeranPhase 2Vaccine—not yet gradedNo reviewed efficacy summary in this indication
ERAS-0015Phase 2Small moleculepan-RASnot yet gradedNo reviewed efficacy summary in this indication
GFH375Phase 2Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
Nuzefatide PevedotinPhase 2PeptideEphA2not yet gradedNo reviewed efficacy summary in this indication
ARV-806
Phase 1/2(overall)
Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
VopimetostatPhase 1/2Small moleculePRMT5not yet gradedNo reviewed efficacy summary in this indication
HSK41959
Phase 1(overall)
Small moleculePRMT5not yet gradedNo reviewed efficacy summary in this indication
LY4066434
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
PF-07934040
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
RG6505
—(overall)
UndisclosedRAS (pan-RAS, RAS-mutant tumors)
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(18 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Rasonque (Daraxonrasib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT06040541 · CT.gov ↗
What to watch
2027 (4)
May 2027 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05-31 · NCT05379985 · CT.gov ↗
What to watch
June 2027 (2)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06 · NCT06162221 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06 · NCT06922591 · CT.gov ↗
What to watch
December 2027 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-01 · NCT06881784 · CT.gov ↗

Company guidance: topline data expected in 2027 (Revolution Medicines, 5 Aug 2026). “Enrollment in the global Phase 3 RASolve 301 trial evaluating daraxonrasib in patients with previously treated RAS mutant NSCLC is expected to be completed this year, supporting an anticipated initial readout in 2027.” Source ↗

What to watch
2028 (5)
April 2028 (2)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-04 · NCT07349537 · CT.gov ↗
What to watch
Phase 3Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2028-04 · NCT07491445 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Solid TumorsRecruiting
Est. primary completion 2028-08-15 · NCT07492680 · CT.gov ↗
What to watch
September 2028 (1)
Phase 1/2Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2028-09-30 · NCT06445062 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12 · NCT06128551 · CT.gov ↗
What to watch
2029 (6)
February 2029 (1)
Phase 1Pancreatic Ductal AdenocarcinomaNot yet recruiting
Est. primary completion 2029-02-17 · NCT07898813 · CT.gov ↗
What to watch
March 2029 (1)
Phase 3Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2029-03 · NCT07805954 · CT.gov ↗
What to watch
May 2029 (2)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-05 · NCT07397338 · CT.gov ↗
What to watch
Phase 3Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2029-05-10 · NCT07252232 · CT.gov ↗
What to watch
June 2029 (1)
Phase 1Pancreatic Cancer, Pancreatic Acinar CarcinomaRecruiting
Est. primary completion 2029-06-01 · NCT07756281 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Biliary Tract Cancer (BTC)Not yet recruiting
Est. primary completion 2029-12 · NCT07908550 · CT.gov ↗
What to watch
2030 (1)
November 2030 (1)
Phase 2Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma …Not yet recruiting
Est. primary completion 2030-11 · NCT07793253 · CT.gov ↗
What to watch
2032 (1)
April 2032 (1)
Phase 1/2Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Neuroblastoma, Recurrent Childhood Rhabdomyosarcoma …Not yet recruiting
Est. primary completion 2032-04-09 · NCT07819838 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

16 November 2026ApprovalEuropean Commission approves Rasonque in previously treated metastatic pancreatic adenocarcinoma
EU, European Commission · Source ↗
26 August 2026ApprovalFDA approves Rasonque (daraxonrasib) in metastatic pancreatic cancer
US, FDA · Source ↗
22 July 2026Filing acceptedFDA accepts the daraxonrasib NDA in previously treated metastatic pancreatic cancer
US, FDA · Revolution Medicines · Source ↗